Author:
Wani Nissar Ahmad,Nasser Mohd W,Ahirwar Dinesh K,Zhao Helong,Miao Zhenhua,Shilo Konstantin,Ganju Ramesh K
Publisher
Springer Science and Business Media LLC
Reference75 articles.
1. Kan N, Kuwata K, Mise K, Kodama H: Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer. Gan To Kagaku Ryoho. 2010, 37: 1259-1264.
2. Guarneri V, Conte P: Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009, 14: 645-656. 10.1634/theoncologist.2009-0078. doi:10.1634/theoncologist.2009-0078
3. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L: Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010, 36: 33-42. 10.1016/j.ctrv.2009.10.001. doi:10.1016/j.ctrv.2009.10.001
4. Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One. 2011, 6: e23901-10.1371/journal.pone.0023901. doi:10.1371/journal.pone.0023901PONE-D-11-12697
5. Kang H, Mansel RE, Jiang WG: Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol. 2005, 26: 1429-1434.
Cited by
91 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献